Windgap Medical develops autoinjector platforms that facilitate the reconstitution and administration of complex injectables, including high-viscosity medications and large volume injections. Their first product enables the rapid delivery of adrenaline for anaphylaxis, addressing the limitations of current injection technologies.
Funding
Funding not disclosed
Founders
Product
Problem
Many injectable drugs, particularly complex formulations like lyophilized powders or high-viscosity medications, require cumbersome reconstitution or multi-step delivery processes, creating challenges for patients and limiting their accessibility. Existing autoinjector technologies often struggle to efficiently handle these complex drug delivery needs.
Solution
Windgap Medical develops innovative autoinjector platforms designed to simplify and automate the delivery of complex injectable drugs, including those requiring powder reconstitution, liquid mixing, or sequential delivery. Their autoinjectors can handle high-viscosity medications (upwards of 5000+ cP) and large volume injections (up to 10 mL). The platforms aim to improve the patient experience and accelerate the path to market for biopharmaceutical companies by offering a more efficient and reliable drug delivery solution.
Target Audience
The primary target audience includes biopharmaceutical companies developing complex injectable drugs and patients who require a simplified and reliable method for self-administration.
Features
- Autoinjector platform for 3-step mixing and administration of lyophilized or powdered compounds.
- Autoinjector platform for 2-step sequential delivery of two liquid therapies through a single needle.
- Compatibility with high-viscosity medications (5000+ cP).
- Capability for large volume injections (up to 10 mL).
- Streamlined drug development process.
- Reduced reconstitution time for lyophilized drugs.